1-4 of 4
Akito Nakamura
Close
Sort by
Journal Articles

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar
Journal: Blood
Blood (2022) 139 (18): 2770–2781.
https://doi.org/10.1182/blood.2021014267
Published: 2022
Includes: Supplemental data
Journal Articles

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Maria Patra-Kneuer, Akito Nakamura, Keli Song, Stephen Grossman, Andrea Polzer, Carmen Ginzel, Stefan Steidl, Allison J Berger, Igor Proscurshim, Christina Heitmüller
Journal: Blood
Blood (2021) 138 (Supplement 1): 2268.
https://doi.org/10.1182/blood-2021-150718
Published: 2021
Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, Vivek Roy, Jeremy T. Larsen, Saulius K. Girnius, Cara A. Rosenbaum, Omar Nadeem, Deborah Berg, Bo Chao, Allison J Berger, Akito Nakamura, Yuhong Zhang, Keli Song, Christine K. Ward, Igor Proscurshim, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2742.
https://doi.org/10.1182/blood-2021-148385
Published: 2021
Journal Articles

New Xenograft Model of Multiple Myeloma and Efficacy of a Humanized Antibody Against Human Interleukin-6 Receptor

Toshiaki Tsunenari, Yasuo Koishihara, Akito Nakamura, Miki Moriya, Hiroyuki Ohkawa, Hideo Goto, Chihiro Shimazaki, Masao Nakagawa, Yoshiyuki Ohsugi, Tadamitsu Kishimoto, Ken-ichi Akamatsu
Journal: Blood
Blood (1997) 90 (6): 2437–2444.
https://doi.org/10.1182/blood.V90.6.2437
Published: 1997